Healthcare / Medical DevicesNasdaqGS
$7.52
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-127.9M · quality 38.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
2/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-1153.7%
↓Gross Margin
N/A
•Debt/Equity
40.35
↑Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
-0.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-143.4M · FCF $2.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | $101.7M | $120.2M | $134.4M | $154.6M | $204.7M | $196.3M | $197.7M | $171.6M | $120.6M |
| Net Income | $-143.4M | $-143.4M | $-162.1M | $-186.6M | $-151.3M | $-143.0M | $-79.0M | $-57.0M | $-29.0M | $-2.3M | $-29.9M | $-178.7M | $-12.9M | $-82.2M | $-15.5M | $-22.2M | $-14.4M | $-13.3M |
| EBITDA | $-4.6M | $-4.6M | $-57.8M | $-117.3M | $-105.8M | $-101.3M | $-47.9M | $-39.7M | $-15.7M | $-1.5M | $-3.0M | $-156.8M | $19.9M | $-47.2M | $14.0M | $-4.6M | $5.5M | $1.8M |
| EPS | -0.96 | -0.96 | -1.13 | -1.54 | -1.46 | -1.49 | -1.18 | — | -1.20 | -1.08 | -3.49 | -21.53 | -1.90 | -0.85 | -0.17 | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | — | 67.1% | 63.3% | 65.5% | 70.9% | 60.7% | 63.1% | 59.1% | 65.7% | 67.2% |
| Operating Margin | — | — | — | — | — | — | — | — | — | -8.8% | -12.8% | -130.9% | 1.0% | -35.9% | -5.0% | -12.4% | -6.9% | -8.4% |
| Net Margin | — | — | — | — | — | — | — | — | — | -2.3% | -24.9% | -133.0% | -8.3% | -40.2% | -7.9% | -11.2% | -8.4% | -11.0% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 40.35 | 40.35 | -40.55 | 6.54 | -10.08 | 4.05 | 0.29 | 1.23 | 2.41 | -1.42 | -1.04 | -0.01 | 0.50 | 0.29 | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $2.8M | $2.8M | $-127.9M | $-159.0M | $-124.6M | $-141.9M | $-69.5M | $-46.2M | $-32.1M | $-16.3M | $-18.9M | $-2.1M | $-31.6M | $-6.5M | $-4.1M | $5.2M | $-28.9M | $-17.3M |
| Returns | ||||||||||||||||||
| ROE | -1153.7% | -1153.7% | 1144.2% | -238.9% | 436.4% | -177.3% | -60.8% | -130.6% | -164.9% | 8.6% | 72.1% | 488.5% | -8.6% | -47.9% | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | -15.4% | -10.5% | -13.1% | -24.5% | 4.3% | -0.7% | 15.2% | 42.3% | — |
| EPS Growth | 15.0% | 15.0% | 26.6% | -5.5% | 2.0% | -26.3% | — | — | -11.1% | 69.1% | 83.8% | -1033.2% | -123.5% | -400.0% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.